RE: Don''''t break out the bubbly just yet. I assume that the info being released is the actual statistical Phase 1A/II results for the 1402 trials. Assuming they have been reviewed by a panel, its hard not to conclude that the results confirm the preliminary data, which was very good. This has to be good news...
I particularly like the company's approach to disclosure in this situation. The company, and 1402, should finally get the widespread publicity that we have been waiting for... and perhaps finally earn back some repsect. The reach of Blood Magazine and the Haemotology Conference itself appears to be very significant.
IF, in fact, there are actually meaningful dialogues going on in the background with potential JV partners on 1402... THEN there is no doubt that PLI's bargaining position in these talks just improved.
If I were a company on the other side of the table negotiating for this product, (competing for this product) and I knew it was about to get this kind of exposure, then I would be pushing to get a deal done and probably be prepared to pay more than ever to get it done beforehand.
Regardless, from a PLI shareholder perspective, the value of 1402 just went up substantially from where I sit....
Having said all that, I just cant fathom why there is a lousy $125K worth of stock on the offer at 37 cents with no real apparent institutional interest.... where the heck is the institutional speculation / realization of this companies growing value ??